One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

Pfizer CEO ‌Albert ‌Bourla on Monday ​flagged issues with the leadership of ‌the ⁠U. Food and ⁠Drug Administration's vaccine ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Dividend Stocks to Invest in Under $50. On March 2, Argus upgraded ...

Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Is Pfizer stock the only big pharma name I'd buy and hold through any market crash? Let's find out. Image source: Getty ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or hold?

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

By Mariam Sunny March 2 (Reuters) - Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad, in response to a ...